Move to topTop

・The $250 million USD expansion demonstrates the company’s continued investment in Colorado and the growing demand for blood plasma.
・The world-class manufacturing plant in Douglas County, Colorado, will produce single-use sets for source plasma collections. 
・The new 170,000-square-foot facility is the second Colorado location for the medical technology company.
・The facility’s integrated sustainability program will focus on reuse and recycling designed for a reduced environmental footprint.


Lakewood, Colo., U.S.A. – 25 May 2022 – Terumo Blood and Cell Technologies, one of Colorado’s largest medical technology companies, today inaugurated its newest manufacturing facility in Douglas County, Colorado. The $250 million USD, state-of-the-art manufacturing plant aligns with the company’s mission of Contributing to Society through Healthcare and serving more patients. Production at the 170,000-square-foot plant will serve source plasma collections customers with single-use collection sets for the recently FDA-cleared Rika Plasma Donation System (Rika).

Terumo Blood and Cell Technologies is a medical technology company specializing in a portfolio of products, software and services for blood component collection, therapeutic apheresis and cellular technologies. 

Rika is a next-generation automated technology focused on the experience of plasma center employees and donors. It was developed in response to the industry's need for technological advancement and process improvements to drive efficiency and quality while maintaining donor safety and a sufficient plasma supply. The Rika technology is an entire ecosystem focused on the operator and donor experience to help meet the worldwide demand for plasma-derived medicines. With an advanced control system to guide device operators, Rika completes plasma collections in 35 minutes or less on average and ensures there is never more than 200 milliliters of blood outside the donor's body at one time.

“Terumo's new manufacturing site in Colorado is a prime example of a strategic investment in an emerging business area,” said Shinjiro Sato, President and CEO,  Terumo Corporation. “Rika will revolutionize plasma collection center operations. This new manufacturing site builds upon our work to Contribute to Society through Healthcare, as we look to plasma-based therapies to touch patients around the globe.”

Rika debuts in 2022 in a limited market release in the Denver, Colorado area. 

“Terumo has been in Colorado for over 50 years,” said Chris Williams, Senior Vice President of Global Manufacturing, Terumo Blood and Cell Technologies. “This new state-of-the-art facility deepens our footprint and financial commitment to the state where we continue to offer quality jobs while making products that touch patients’ lives every second of every day. At full capacity, we plan to operate 24/7 with four production lines that are optimized for efficiency with highly automated precision manufacturing.”

The new facility will eventually employ about 300 people based on market needs. Terumo Blood and Cell Technologies maintains its Douglas County campus with manufacturing clean rooms that are evolving to a high-tech process facility.
The facility will also integrate a robust and efficient reuse and recycling program. At full production volume, this effort will ensure that several hundred tons of plastic are recycled, and more than a million pounds of wood will be conserved annually.  

“Colorado continues to be a hot spot for bioscience companies,” said Elyse Blazevich, President and CEO, Colorado BioScience Association.“Terumo’s expansion here validates the sector’s continued growth and prospects.”


About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. 
Terumo Blood and Cell Technologies’ customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers, plasma centers and private medical practices. Our customers are based in over 130 countries. 
Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology. For more information, visit 

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.